Key Takeaways SGHT announced a published meta-analysis validating OMNI's long-term safety and efficacy.SGHT's OMNI was shown to reduce IOP and medication use with durable outcomes.SGHT reported that nearly 89% of patients achieved at least 20% IOP reduction at 6, 12 and 24 months.Sight Sciences (SGHT) recently announced the publication of a systematic literature review and meta-analysis in the European Journal of Ophthalmology, highlighting the long-term safety and efficacy of the OMNI Surgical System (OMNI ...

The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucomaMENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and impr ...